

Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS -Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:09:22 ON 23 SEP 2005

=> file caplus uspatful japio eptfull medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 12:09:40 ON 23 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:09:40 ON 23 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 12:09:40 ON 23 SEP 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'EPFULL' ENTERED AT 12:09:40 ON 23 SEP 2005
COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 12:09:40 ON 23 SEP 2005

FILE 'BIOSIS' ENTERED AT 12:09:40 ON 23 SEP 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:09:40 ON 23 SEP 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:09:40 ON 23 SEP 2005
Copyright (c) 2005 The Thomson Corporation

=> s 3(w)deazadaadenosine
L1 0 3(W) DEAZADAADENOSINE

=> s 3(w)deazaadenosine
L2 1645 3(W) DEAZAADENOSINE

=> s L2 aqnd analog
MISSING OPERATOR L2 AQND
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> .
. IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L2 and analog?
L3 607 L2 AND ANALOG?

=> s l3 and stent?
L4 4 L3 AND STENT?

=> s l4 and covalent?
L5 3 L4 AND COVALENT?

=> d l5 1-3 ibib abs

L5 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:139387 USPATFULL
TITLE: 3-deazaadenosine prevents
atherosclerosis and graft vasculopathy
INVENTOR(S): Haberbosch, Werner, Giessen, GERMANY, FEDERAL REPUBLIC
OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004106563	A1	20040603
APPLICATION INFO.:	US 2003-655225	A1	20030904 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-786672, filed on 6 Apr 2001, GRANTED, Pat. No. US 6693088 A 371 of International Ser. No. WO 1999-EP6462, filed on 2 Sep 1999, UNKNOWN		

NUMBER DATE

 PRIORITY INFORMATION: EP 1998-116658 19980903
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY,
 10103-3198
 NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Page(s)
 LINE COUNT: 591
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to the use of **3-deazaadenosine**
 and **analogs** thereof for the manufacture of a medicament
 against vascular diseases or graft rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 3 USPATFULL on STN
 ACCESSION NUMBER: 2004:41456 USPATFULL
 TITLE: **3-deazaadenosine** prevents
 atherosclerosis and graft vasculopathy
 INVENTOR(S): Haberbosch, Werner, Giessen, GERMANY, FEDERAL REPUBLIC
 OF
 PATENT ASSIGNEE(S): Kerckhoff-Klinik Gesellschaft MIT Beschränkter Haftung,
 Bad Nauheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6693088	B1	20040217
	WO 2000013691		20000316
APPLICATION INFO.:	US 2001-786672		20010406 (9)
	WO 1999-EP6462		19990902

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-116658	19980903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Spivack, Phyllis G.	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski L.L.P.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	590	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Vascular diseases and graft rejection are treated or prevented with 3-deazaadenosine and analogs thereof.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 3 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN
 ACCESSION NUMBER: 1999:95000 EPFULL
 ENTRY DATE PUBLICATION: 20050720
 UPDATE DATE PUBLICAT.: 20050907
 DATA UPDATE DATE: 20050907
 DATA UPDATE WEEK: 200536
 TITLE (ENGLISH): BIOACTIVE PROSTHESES OF A CONDUCTIVE MATERIAL COATED
 WITH A POLYMER AND A SUBSTANCE WITH IMMUNOSUPPRESSIVE,
 ANTISTENOTIC AND ANTITHROMBOTIC PROPERTIES
 TITLE (FRENCH): PROTHESES BIOACTIVES EN MATERIAU CONDUCTEUR REVETU D'UN
 POLYMER ET D'UNE SUBSTANCE A PROPRIETES

TITLE (GERMAN): IMMUNOSUPPRESSIVES, ANTISTENOSE ET ANTITHROMBOSE
BIOAKTIVE PROTHESEN AUS LEITENDEM MATERIAL BESCHICHTET
MIT EINEM POLYMER UND EINER SUBSTANZ MIT
IMMUNSUPPRESSIVEN, ANTISTENOSEN UND ANTITHROMBOSEN
EIGENSCHAFTEN

INVENTOR(S): LE MOEL, Alain, 1, rue du Colonel Marchand, F-92370
Chaville, FR; BETZ, Natacha, 13 bis, rue Alfred
Laurent, F-92100 Boulogne-Billancourt, FR; BUREAU,
Christophe, 1 Residence des Champs Lasniers, Bat. K,
F-91940 Les Ulis, FR; DENIAU, Guy, 5, allée de la
Ferme, F-78610 Auffargis, FR; BAQUEY, Charles, 33,
rue du Haillan, F-33160 Le Haillan, FR; DELERIS,
Gerard, 4, rue du Livran, F-33000 Bordeaux, FR;
HABERBOSCH, Werner, Bechsteinweg 6, D-35398 Giessen,
DE

PATENT APPLICANT(S): COMMISSARIAT A L'ENERGIE ATOMIQUE, 31/33, rue de la
Federation, 75015 Paris Cedex 15, FR; INSTITUT NATIONAL
DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
101, rue de Tolbiac, 75654 Paris Cedex 13, FR;
Kerckhoff-Klinik GmbH, Benkestrasse 2-8, 61231 Bad
Nauheim, DE

PATENT APPL. NUMBER: 200903; 248490; 2944411

AGENT: Audier, Philippe Andre, et al, Brevaux, 3, rue du
Docteur Lancereaux, 75008 Paris, FR

AGENT NUMBER: 91673

LANGUAGE OF FILING: French

LANGUAGE OF PUBL.: French

LANGUAGE OF PROCEDURE: French

LANGUAGE OF TITLE: German; English; French

DOCUMENT TYPE: Patent

PATENT INFO TYPE: EPB1 Granted patent

PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE
EP 1131113	B1	20050720
WO 2000029043		20000525

DESIGNATED STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT
SE

APPLICATION INFO.: EP 1999-972115 A 19991115
WO 1999-FR2795 A 19991115

PRIORITY INFO.: FR 1998-14351 A 19981116

CITED NON PATENT LIT.: DEGERT C., DUPUY B., LABAT B. AND BAQUEY CH.:
"Association of Polyacrylamide beads to polyethylene
terephthalate prostheses" BIOMAT., ART. CELLS & IMMOB.
BIOTECH., vol. 21, no. 4, 1993, pages 553-561,
XP002111293 cite dans la demande;
BAQUEY CH., BEZIADE A., DUCASSOU D. ET BLANQUET P.:
"Interet du Greffage Radiochimique de Monomeres
Vinyliques pour ameliorer l'hemocompatibilite des
Materiaux artificiels" INNOV. TECH. BIOL. MED., vol. 2,
no. 4, 1981, pages 378-389, XP002111294 cite dans la
demande

CITED PATENT LIT.: EP 596615 A
EP 873732 A
EP 940144 A
FR 2187849 A
US 4879135 A


[About Us](#)
[Newsroom](#)
[Advisory Board](#)
[Submit Web Site](#)
[Search Tips](#)
[Contact Us](#)
[Basic Search](#)
[Advanced Search](#) [Search Preferences](#)

☒ Journal sources ☒ Preferred Web sources ☒ Other Web sources ☐ Exact phrase

Searched for:: :All of the words:(3 AND deazaadenosine) and stent


 Found:: :29 total | [1 journal results](#) | [12 preferred web results](#) | [16 other web results](#)

 Sort by:: :[relevance](#) | [date](#)

- ☐ 1. **3-DEAZAADENOSINE PREVENTS ATHEROSCLEROSIS AND GRAFT VASCULOPATHY**
HABERBOSCH, Werner / KERCKHOFF-KLINIK GESELLSCHAFT MIT BESCHRÄ /
NKTER HAFTUNG, PATENT COOPERATION TREATY APPLICATION, Mar 2000
 ...preferred indications of **3-deazaadenosine** and analogs thereof are...interventions,
 especially after **stent**-implantation. Restenosis in stents On-**stent** restenosis) can be
 prevented by coating the **stent** to be used with **3-deazaadenosine**. The combination...
Full text available at patent office. For more in-depth searching go to **LexisNexis**
[similar results](#)
- ☐ 2. **"Molecular Chameleons": Design and Synthesis of a Second Series of Flexible Nucleosides**
Salim, Samer, Dec 2004
 ...derivatives of Ari and NpcA 38 Figure 26 **3-Deazaadenosine** (a potent inhibitor of
 SAHase) and S-3- Deazaadenosyl homocysteine 38 Figure...fleximer targets 104 Figure
 52 Proximal **3-deazaadenosine** fleximer 105 Figure 53 Carbocyclic proximal...
Full text thesis available via NDLTD
[similar results](#)
- ☐ 3. **Allele-Specific Regulation of Matrix Metalloproteinase-12 Gene Activity Is Associated With**
Coronary Artery Luminal Dimensions ... [73K]
Shu Ye , Joseffa Moritz , Dirk H. Walter , / Stefanie Dimmeler , / Andreas M.
Zeiber , / Adriano Henney , / Anders Hamsten , Aug 2005
 ...coronary angiography with **stent** implantation were genotyped...atherosclerotic
 plaques. 2 3 4 5 6 7 The regulation...48 hours. Lanes 1 and 3, Unstimulated cells
 lanes...Patients Undergoing PTCA With **Stent** Implantation To analyze...who underwent
 PTCA with **stent** implantation were genotyped...
[\[http://ahavj.ahajournals.org/cgi/content/full/circresa...\]](http://ahavj.ahajournals.org/cgi/content/full/circresa...)
[similar results](#)
- ☐ 4. **WATER-SOLUBLE COMPOUND**
TUSZYNSKI, Jack / GREENWALD, Howard, J. / CURRY, Stephen, H. / GOSS,
Kendrick / TECHNOLOGY INNOVATIONS, LLC, PATENT COOPERATION TREATY
APPLICATION, May 2005
 ...development settings," Adv. Drug Delivery Rev., 1997, 23(1-3), 3-25. In this article, it
 was disclosed that: "In the USAN set...Pfizer and co-workers in Adv. Drug Delivery Rev.,

 Re
us
for
adl
alu
bio
col
eni
gly
gly
iso
mi
pa
Or
Al
F

vol. 23, pp. 3-25 (1997). The 'rule of 5' is focused on drug permeability...

Full text available at patent office. For more in-depth searching go to  **similar results**

☐ **5. No Title** [242K]

Jul 2003

...Nodes: 10346 Sorted by LCS Page 14 1 2 **3** 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
19...human systemic lupus erythematosus 17 0 6502 **3** 3989 2000 MOLECULAR
MEMBRANE BIOLOGY 17...3990 2000 MOLECULAR MEMBRANE BIOLOGY 17(**3**):157-164
Williams EE Cooper JA Stillwell...

more hits from [<http://garfield.library.upenn.edu/histcomp/celldeathdi...>]

similar results

☐ **6. Jahresbericht 2002 des FB Medizin der JLU Giessen** [PDF-2MB]

Feb 2005

...Justus-Liebig-Universität Gießen Anschrift: Dekanat Fachbereich Medizin Rudolf-
Buchheim-Str. 6 35392 Gießen **3** Inhaltsverzeichnis Seite Berichte Publikationen
Inhaltsverzeichnis **3** BERICHT DES DEKANS 6 Personalia...

[<http://www.med.uni-giessen.de/infoweb/dekanat/jahresbe...>]

similar results

☐ **7. COMPOSITIONS AND METHODS FOR IMPROVING INTEGRITY OF COMPROMISED BODY
PASSAGEWAYS AND CAVITIES**

**SIGNORE, Pierre, E. / MACHAN, Lindsay, S. / ANGIOTECH INTERNATIONAL AG,
EUROPEAN PATENT**, Dec 2001

...16(2):125-134, 1991), tubercidin (7-**deazaadenosine**) (Mooberry et al., Cancer Lett .
96(2):261-266, 1995), 2-amino-4-(**3**-pyridyl)- 4H-naphtho(1,2-b)pyran-**3**-carbonitrile
(Panda et al., J. Biol. Chem...1997 Wood et al., Mol . Pharmacol . 52(**3**) :437-444, 1997),
aluminum fluoride (Song...

Full text available at patent office. For more in-depth searching go to  **similar results**

☐ **8. No Title** [PDF-47K]

Mar 2003

...LQVFKHUI 5, Metz J, Kübler W, Hehrlein C (1997). Apoptosis after **stent** implantation
compared with balloon angioplasty in rabbits. The...irradiation via an activated guide-wire
on neointima formation after **stent** implantation. &LUFXODWLRQ (Suppl. I) 92: I -
146 .LQVFKHUI 5...

[http://www.dkfz.de/tzhdma/texte/tzprkinscherf_pv.pdf]

similar results

☐ **9. Clinical Chemistry -- Topical Collections : Lipids, Lipoproteins, and Cardiovascular Risk
Factors** [25K]

Jan 2005

...Revascularization after Coronary Artery **Stent** Placement Saskia Z.H. Rittersma,
Robbert...Extract] [Full text] Letters to the Editor **3-Deazaadenosine**, a Stabilizer of
Whole-Blood Homocysteine...Previous page] [Next page] Pages: 1 2 **3** 4 5 6 7 8 9 10 11
12 13 14 15 16 17 18...

more hits from [<http://www.clinchem.org/cgi/collection/LAL?page=4>]

similar results

☐ **10. Member Publications 2004** [215K]

Jun 2005

...independent of cell cycle association. Cell Cycle **3**:205-211, 2004. Akst LM, Chan J,
Elson P...associates with human parainfluenza virus type **3** ribonucleoprotein complex
and activates transcription...nucleolin in human parainfluenza virus type **3** infection of
human lung epithelial cells...




[<http://cancer.case.edu/research/Pubs%202004.htm>]

similar results

11. Inhibition of {alpha}4 Integrin and ICAM-1 Markedly Attenuate Macrophage Homing to

- ☐ Atherosclerotic Plaques in ApoE-Deficient ... [145K]
S. Patel / Thiagarajan, MD James T / Willerson, MD Edward T / H. Yeh, Jan 2005
 ...adherence to activated endothelial cells. 2 **3** After transmigration across the endothelial...the intraperitoneal injection of 1 mL of **3**% aged Brewer's thioglycolate (Difco Laboratories...the tail vein in a total volume of 0.2 to 0.3 mL of HBSS. All animals were killed 48 hours...
[\[http://circ.ahajournals.org/cgi/content/full/97/1/75\]](http://circ.ahajournals.org/cgi/content/full/97/1/75)
similar results
- ☐ **12.** No Title [PDF-325K]
 Mar 2004
 ...Contents
 **3** List of Illustrations
[\[http://www.creighton.edu/GradSchool/facbib2003/facbib2...\]](http://www.creighton.edu/GradSchool/facbib2003/facbib2...)
similar results
- ☐ **13.** Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic ... [71K]
 Oct 2004
 ...Inflammation and Restenosis in the **Stent** Era Arterioscler. Thromb. Vasc...Vasc. Biol., March 1, 2002 22(**3**): 361 - 363. [Full Text] [PDF...Dullaues, and W. Haberbosch **3-Deazaadenosine** Prevents Adhesion Molecule Expression...Vasc. Biol., March 1, 1999 19 (**3**): 784 - 793. [Abstract] [Full...
[\[http://atvb.ahajournals.org/cgi/content/abstract/14/5/...\]](http://atvb.ahajournals.org/cgi/content/abstract/14/5/...)
similar results
- ☐ **14.** Inhibition of {alpha}4 Integrin and ICAM-1 Markedly Attenuate Macrophage Homing to Atherosclerotic Plaques in ApoE-Deficient ... [83K]
 Nov 2004
 ...Molecule-1-Deficient Mice Circ. Res., March **3**, 2000 86(4): 434 - 440. [Abstract] [Full...Activators Circulation, January 25, 2000 101(**3**): 235 - 238. [Abstract] [Full Text...C. Braun-Dullaues, and W. Haberbosch **3-Deazaadenosine** Prevents Adhesion Molecule Expression...
[\[http://www.circ.ahajournals.org/cgi/content/abstract/9...\]](http://www.circ.ahajournals.org/cgi/content/abstract/9...)
similar results
- ☐ **15.** The AMEDEO Literature Guide [109K]
 Dec 2004
 ...PUNCTURE VERSUS COLON ASCENDENS **STENT** PERITONITIS: TWO DISTINCT ANIMAL...lipopolysaccharide-induced interferon regulatory factor **3** activation and protection from...with sepsis. Shock 200320:582-**3**. PubMed Related articles MCDONALD...and puncture. Shock 2003 19: 310-**3**. PubMed Related articles Abstract...
[\[http://www.amedeo.com/medicine/sep/shock.htm\]](http://www.amedeo.com/medicine/sep/shock.htm)
similar results
- ☐ **16.** Facts and Recommendations about Total [PDF-156K]
 Jan 2005
 ...Helga Refsum,1,2* A. David Smith,1 Per M. Ueland,**3** Ebba Nexø,4 Robert Clarke,5 Joseph McPartlin,6...diluting the plasma (46). Adenosine analogs, such as **3-deazaadenosine**, are effective Fig. **3**. Time- and temperature-dependent increase in tHcy...
[\[http://www.uib.no/people/mfapu/PMU%20Media/papers%20pd...\]](http://www.uib.no/people/mfapu/PMU%20Media/papers%20pd...)
similar results
- ☐ **17.** Subject Index
Journal of the American College of Cardiology, Feb 2001
 ...February 2001 Subject Index Ablation-catheter **3-D** Distribution of Bipolar Atrial Electrogram...American Men With Coronary Artery Disease 821-**3**-327A Right Ventricular Function Is a Predictor...Ischemia Syndrome Evaluation (WISE) Study 817-**3**-243A Abnormalities in Nitric Oxide Synthase...

Full text article available from  [similar results](#)

- ☐ **18. USE OF ANTI-MICROTUBULE AGENTS FOR TREATING INFLAMMATORY RESPIRATORY DISEASES OF THE RESPIRATORY TRACT**
Hunter, William L. / Angiotech International GmbH, EUROPEAN PATENT, Apr 2001
 ...re-establish nasal breathing and olfaction and (3) to prevent recurrence. Occlusion of the...methyl-2,4-pentanediol), tubercidin (7-**deazaadenosine**), LY290181 (2-amino-4-(3-pyridyl)-4H-naphtho(1,2-b)pyran-3-cardonitrile), aluminum fluoride, ethylene...
Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ **19. USE OF ANTI-MICROTUBULE AGENTS FOR TREATING INFLAMMATORY BOWEL DISEASES**
Hunter, William L. / Angiotech International GmbH, EUROPEAN PATENT, Jan 2001
 ...2-methyl-2,4-pentanediol), tubercidin (7-**deazaadenosine**), LY290181 (2-amino-4-(3-pyridyl)-4H-naphtho(1,2-b)pyran-3-cardonitrile), aluminum fluoride, ethylene...µM, (▴) 28 µM, (&sq;) 46 µM n=3. Figure 1B is a graph which shows the...
Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ **20. BIODEGRADABLE POLYMER**
WANG, Yadong / AMEER, Guillermo / LANGER, Robert, S. / MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PATENT COOPERATION TREATY APPLICATION, Aug 2003
 ...biocompatible polymer. Both the coated **stent** and the polymeric **stent** may include a small molecule or a bioactive...2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, C5-propynylcytidine...C5-iodouridine, C5-methylcytidine, 7-**deazaadenosine**, 7-deazaguanosine, 8-oxoadenosine, 8...
Full text available at patent office. For more in-depth searching go to  [similar results](#)



Results Pages: [[<< Prev](#)] 1 2 [[Next >>](#)]

[back to top](#)




[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005






3-DEAZAADENOSINE PREVENTS ATHEROSCLEROSIS AND GRAFT VASCULOPATHY

Patent number: WO0013691
Publication date: 2000-03-16
Inventor: HABERBOSCH WERNER (DE)
Applicant: KERCKHOFF KLINIK GES MIT BESCH (DE);
HABERBOSCH WERNER (DE)
Classification:
- international: A61K31/70
- european: A61K31/70R10P10
Application number: WO1999EP06462 19990902
Priority number(s): EP19980116658 19980903

Also published as:

 WO0013691 (A3)
 WO0013691 (A3)
 US6693088 (B1)

Cited documents:

 EP0010668
 EP0038567
 XP002093416
 XP002093417
 XP002093418
more >>

[Report a data error here](#)

Abstract of WO0013691

The invention relates to the use of 3-deazaadenosine and analogs thereof for the manufacture of a medicament against vascular diseases or graft rejection.

.....
Data supplied from the **esp@cenet** database - Worldwide